Atai Life Sciences announced that it has invested a total of $50 million to acquire 35.5% of Beckley Psytech, which is developing BPL-003 intranasal synthetic 5-MeO-DMT (mebufotenin). Atai's subsidiary Innaris Bio is developing a gelling excipient for use in intranasal drugs for the treatment of mental health disorders. The deal includes the right of first … [Read more...] about Atai Life Sciences announces strategic investment in Beckley Psytech
News
MannKind sells 1% royalty in Tyvaso treprostinil DPI for up to $200 million
According to MannKind Corporation, Sagard Healthcare is paying $150 million and a potential milestone payment of as much as $50 million for a 1% royalty on net sales of Tyvaso treprostinil DPI between October 1, 2023 and December 31, 2042. Tyvaso DPI is marketed by United Therapeutics, which licensed Treprostinil Technosphere from MannKind Corporation in September … [Read more...] about MannKind sells 1% royalty in Tyvaso treprostinil DPI for up to $200 million
NanoPhoria publishes data on the efficacy of its inhaled lung-to-heart therapy in a pig model
Italian start-up NanoPhoria has announced the publication of an article titled “Lung-to-Heart Nano-in-Micro Peptide Promotes Cardiac Recovery in a Pig Model of Chronic Heart Failure” in the Journal of the American College of Cardiology (JACC). The study, which evaluated a dry powder inhalation formulation of mimetic peptide loaded onto calcium phosphate nanoparticles … [Read more...] about NanoPhoria publishes data on the efficacy of its inhaled lung-to-heart therapy in a pig model
Firebrick no longer seeking approval of Nasodine nasal spray in Australia
Firebrick Pharmaceuticals announced that it has withdrawn its appeal of a decision by the Therapeutic Goods Administration (TGA), which refused to approve the company's Nasodine povidone-iodine nasal spray as a treatment for the common cold. Firebrick said that the withdrawal was due to "the significant distraction and legal costs associated with proceeding," … [Read more...] about Firebrick no longer seeking approval of Nasodine nasal spray in Australia
FDA issues Refuse to File letter in response to Milestone’s NDA for etripamil nasal spray
According to Milestone Pharmaceuticals, the FDA has refused to file the company's NDA for etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia (PSVT) and has "requested clarification about the time of data recorded for adverse events" during Phase 3 trials. Milestone submitted the NDA in October 2023. Milestone initiated the Phase 3 … [Read more...] about FDA issues Refuse to File letter in response to Milestone’s NDA for etripamil nasal spray
Court upholds PTAB ruling invalidating United Therapeutics’ patent at center of suit delaying final approval Liquidia’s Yutrepia treprostinil DPI
According to Liquidia Corporation, the company will immediately take steps toward getting final FDA approval of Yutrepia treprostinil DPI now that the US Court of Appeals has upheld a decision by the Patent Trial and Appeal Board (PTAB) invalidating all of the claims of US Patent No. 10,716,793. Earlier this year, the Court of Appeals upheld a District Court ruling … [Read more...] about Court upholds PTAB ruling invalidating United Therapeutics’ patent at center of suit delaying final approval Liquidia’s Yutrepia treprostinil DPI
Harm Reduction announces availability of RiVive naloxone nasal spray in the US
Non-profit Harm Reduction Therapeutics (HRT) announced that it has filled the first order for RiVive naloxone nasal spray, which was approved by the FDA in July 2023 as an over-the-counter medication for the treatment of opioid overdose. RiVive, which is being manufactured by Catalent at its Morrisville, North Carolina facility, will be more available more broadly in … [Read more...] about Harm Reduction announces availability of RiVive naloxone nasal spray in the US
Tiziana initiates Phase 2a trial of intranasal foralumab in non-active secondary-progressive MS
Tiziana Life Sciences announced the initiation of a Phase 2a study of intranasal foralumab in patients with non-active secondary-progressive multiple sclerosis (na-SPMS), with a primary endpoint of change in microglial activation as determined by PET scan. The trial will evaluate 2 doses of foralumab versus placebo and is expected to enroll 18 patients in each arm of … [Read more...] about Tiziana initiates Phase 2a trial of intranasal foralumab in non-active secondary-progressive MS
Vivaldi gets grant to fund preclinical transmission study of its DeltaFlu intranasal universal flu vaccine
Vivaldi Biosciences announced that the Flu Lab has provided a grant to fund a transmission study of the company's DeltaFLU intranasal universal influenza vaccine. According to the company, the study will evaluate the ability of DeltaFlu to protect against transmission of "broadly divergent wild-type influenza type A and B strains" among ferrets. The company noted … [Read more...] about Vivaldi gets grant to fund preclinical transmission study of its DeltaFlu intranasal universal flu vaccine
Ethris initiates Phase 1 trial of nasal and inhaled delivery of ETH47 mRNA therapy
After recently receiving authorization for a Phase 1 trial of its ETH47 mRNA therapy, Ethris has initiated the study, the company announced. The trial is expected to enroll 88 healthy participants aged 18 to 55 and will evaluate the safety, tolerability, and pharmacokinetics of both nasal and inhaled delivery of ETH47, as well as combined nasal/inhaled delivery. The … [Read more...] about Ethris initiates Phase 1 trial of nasal and inhaled delivery of ETH47 mRNA therapy